[Long-term sequelae of cancer survivors].
Standard
[Long-term sequelae of cancer survivors]. / Schilling, Georgia; Arnold, Dirk.
in: BUNDESGESUNDHEITSBLA, Jahrgang 55, Nr. 4, 4, 2012, S. 493-500.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Long-term sequelae of cancer survivors].
AU - Schilling, Georgia
AU - Arnold, Dirk
PY - 2012
Y1 - 2012
N2 - Multimodal treatment modalities enable an increasing number of patients with malignant diseases to become candidates for a curatively intended treatment strategy. Furthermore, for numerous patients with incurable cancer disease, new therapeutic developments (including molecular "targeted" agents) allow control of further progression of tumor growth for months up to years - and therefore, even those patients may be regarded as having a "chronic" disease. Taken together, both patient groups increase the number of "long-term cancer survivors" markedly. However, complex interdisciplinary therapeutic strategies and the increasing number of options for sequential treatments also result in higher rates of acute and chronic toxicities and sequelae. Even years after completion of the initial treatment, many cancer survivors still suffer from sequelae of both malignant disease and therapy. This refers to both psychosocial and somatic involvement. In consequence, a focus of (future) oncology care - beyond successful oncology treatment rates - is to carefully investigate the somatic and psychosocial aspects of long-term sequelae in order to treat them, or - using appropriate preventative measures - to limit or even prevent their occurrence.
AB - Multimodal treatment modalities enable an increasing number of patients with malignant diseases to become candidates for a curatively intended treatment strategy. Furthermore, for numerous patients with incurable cancer disease, new therapeutic developments (including molecular "targeted" agents) allow control of further progression of tumor growth for months up to years - and therefore, even those patients may be regarded as having a "chronic" disease. Taken together, both patient groups increase the number of "long-term cancer survivors" markedly. However, complex interdisciplinary therapeutic strategies and the increasing number of options for sequential treatments also result in higher rates of acute and chronic toxicities and sequelae. Even years after completion of the initial treatment, many cancer survivors still suffer from sequelae of both malignant disease and therapy. This refers to both psychosocial and somatic involvement. In consequence, a focus of (future) oncology care - beyond successful oncology treatment rates - is to carefully investigate the somatic and psychosocial aspects of long-term sequelae in order to treat them, or - using appropriate preventative measures - to limit or even prevent their occurrence.
KW - Comorbidity
KW - Humans
KW - Health Status
KW - Germany/epidemiology
KW - Mortality/trends
KW - Life Expectancy/trends
KW - Survivors/statistics & numerical data
KW - Causality
KW - Neoplasms/mortality/psychology
KW - Chronic Disease/mortality/psychology
KW - Mental Disorders/epidemiology/psychology
KW - Comorbidity
KW - Humans
KW - Health Status
KW - Germany/epidemiology
KW - Mortality/trends
KW - Life Expectancy/trends
KW - Survivors/statistics & numerical data
KW - Causality
KW - Neoplasms/mortality/psychology
KW - Chronic Disease/mortality/psychology
KW - Mental Disorders/epidemiology/psychology
M3 - SCORING: Zeitschriftenaufsatz
VL - 55
SP - 493
EP - 500
JO - BUNDESGESUNDHEITSBLA
JF - BUNDESGESUNDHEITSBLA
SN - 1436-9990
IS - 4
M1 - 4
ER -
